High-Risk Low-Grade Gliomas
Conditions
Interventions
Experimental:radiotherapy plus temozolomide
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Supratentorial WHO grade II astrocytoma, oligodendroglioma, or mixed oligo-astrocytoma; 2. Aged 18 to 39 years with subtotal resection/biopsy, or aged 40 to 70 years with any extent of resection/biopsy; 3. Karnofsky performance score (KPS) = 60; (no, mild, or moderate neurologic symptoms and signs); 4. Patients have to be entered onto the study within 12 weeks of surgery; 5. Have signed consent form.
Exclusion criteria
Exclusion criteria: 1. WHO grade 1 gliomas or high-grade gliomas; 2. tumors spread to noncontiguous cranial or spinal leptomeninges; 3. gliomatosis cerebri; 4. have accepted prior chemotherapy or radiation therapy to the brain or head and neck region; 5. synchronous malignancy excluding carcinoma of the cervix in situ or nonmelanomatous skin cancer; 6. prior malignancy unless disease-free survival for more than 5 years; 7. have active infection or patients are pregnant,breast-feeding,or unable or unwilling to consider the use of effective contraception during treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;cognitive function;adverse events; | — |
Countries
China
Contacts
Public ContactPing Ai
Department of Head and neck oncology, West China Hospital, Sichuan University
Outcome results
None listed